Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Atovaquone

FDA-approved product (tablet, oral), marketed as Atovaquone, Mepron.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Atovaquone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Amebiasis
  • Malaria
  • Pneumocystosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other agents against amoebiasis and other protozoal diseases
FDA pharmacologic class
Antimalarial; Antiprotozoal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01AX06; FDA class Antimalarial; FDA class Antiprotozoal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA30.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli14.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Atovaquone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Atovaquone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)

    NCT07357103 · start 2026-03

    Registered record
    Registry ID
    NCT07357103
    Conditions
    Pneumocystis; Pneumocystis Infection; Pneumocystis Carinii Infection; Pneumocystis Carinii; Infection, Resulting From HIV Disease; Pneumocystis Jirovecii Pneumonia; Pneumocystis Jirovecii Infection; Pneumocystosis Associated With AIDS; Pneumocystosis; Pneumonia (Etiology)
    Interventions
    Clindamycin + primaquine; Pentamidine; Atovaquone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-03
    Completion
    2029-09
    Enrolment
    416

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumocystis; Pneumocystis Infection; Pneumocystis Carinii Infection; Pneumocystis Carinii +6 more
    InterventionClindamycin + primaquine; Pentamidine; Atovaquone
    PhasePhase 4
    Registry statusNot yet recruiting

  • First-in-Human PfSPZ-LARC2 Vaccination/CHMI

    NCT06735209 · start 2025-07-23

    Registered record
    Registry ID
    NCT06735209
    Conditions
    Malaria
    Interventions
    PfSPZ Vaccine; PfSPZ (7G8) Challenge; Sodium Chloride, 0.9%
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-07-23
    Completion
    2026-07-10
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionPfSPZ Vaccine; PfSPZ (7G8) Challenge; Sodium Chloride, 0.9%
    PhasePhase 1
    Registry statusCompleted

  • Atovaquone Combined With Radiation in Children With Malignant Brain Tumors

    NCT06624371 · start 2025-03-28

    Registered record
    Registry ID
    NCT06624371
    Conditions
    High-grade Glioma; Medulloblastoma; Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma, H3 K27M-Mutant
    Interventions
    Atovaquone; Radiation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2025-03-28
    Completion
    2027-10
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh-grade Glioma; Medulloblastoma; Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma, H3 K27M-Mutant
    InterventionAtovaquone; Radiation Therapy
    PhasePhase 1
    Registry statusRecruiting

  • A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)

    NCT06294912 · start 2024-04-18

    Registered record
    Registry ID
    NCT06294912
    Conditions
    Malaria
    Interventions
    Plasmodium falciparum; MK-7602; Artemether/lumefantrine; Primaquine; Artesunate; Atovaquone/proguanil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-04-18
    Completion
    2025-01-06
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionPlasmodium falciparum; MK-7602; Artemether/lumefantrine; Primaquine +2 more
    PhasePhase 1
    Registry statusCompleted

  • Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)

    NCT05974267 · start 2023-11-28

    Registered record
    Registry ID
    NCT05974267
    Conditions
    Malaria Infection
    Interventions
    M5717 60 mg; Pyronaridine; Atovaquone-Proguanil; M5717 200 mg; M5717 660mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-11-28
    Completion
    2024-12-29
    Enrolment
    192

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria Infection
    InterventionM5717 60 mg; Pyronaridine; Atovaquone-Proguanil; M5717 200 mg +1 more
    PhasePhase 2
    Registry statusCompleted

  • Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

    NCT05998135 · start 2023-11-09

    Registered record
    Registry ID
    NCT05998135
    Conditions
    Ovarian High Grade Serous Adenocarcinoma; Platinum-Resistant Ovarian Carcinoma
    Interventions
    Atovaquone; Biopsy; Computed Tomography; Paracentesis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-11-09
    Completion
    2027-06-30
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian High Grade Serous Adenocarcinoma; Platinum-Resistant Ovarian Carcinoma
    InterventionAtovaquone; Biopsy; Computed Tomography; Paracentesis
    PhasePhase 2
    Registry statusRecruiting

  • Atoguanil BA Study

    NCT04866602 · start 2021-11-17

    Registered record
    Registry ID
    NCT04866602
    Conditions
    Bioavailability
    Interventions
    Atoguanil; Malarone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-11-17
    Completion
    2022-03-18
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBioavailability
    InterventionAtoguanil; Malarone
    PhasePhase 1
    Registry statusCompleted

  • P-Co-Li (Pulmonary Covid-19 Study)

    NCT04782700 · start 2021-04-01

    Registered record
    Registry ID
    NCT04782700
    Conditions
    Covid19; Lung Inflammation; Hypoxemic Respiratory Failure
    Interventions
    Steroid Taper (Prednisone)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2021-04-01
    Completion
    2021-06-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19; Lung Inflammation; Hypoxemic Respiratory Failure
    InterventionSteroid Taper (Prednisone)
    PhaseNot applicable
    Registry statusWithdrawn

  • Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC

    NCT04648033 · start 2020-12-07

    Registered record
    Registry ID
    NCT04648033
    Conditions
    Locally Advanced Non-Small Cell Lung Cancer
    Interventions
    Atovaquone Oral Suspension; Standard of care chemotherapy; Standard of care radiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-12-07
    Completion
    2023-10-02
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Non-Small Cell Lung Cancer
    InterventionAtovaquone Oral Suspension; Standard of care chemotherapy; Standard of care radiotherapy
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate the Influence of Tegoprazan on the Pharmacokinetics of Proguanil in Healthy Volunteers

    NCT04568772 · start 2020-11-25

    Registered record
    Registry ID
    NCT04568772
    Conditions
    Gastroesophageal Reflux Disease
    Interventions
    Atovaquone / Proguanil 250/100 mg; Tegoprazan 50 mg; Esomeprazole 40 mg; Vonoprazan 20 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-11-25
    Completion
    2021-08-03
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroesophageal Reflux Disease
    InterventionAtovaquone / Proguanil 250/100 mg; Tegoprazan 50 mg; Esomeprazole 40 mg; Vonoprazan 20 mg
    PhasePhase 1
    Registry statusCompleted

  • A Clinical Trial to Evaluate Plasmodium Falciparum 7G8 and NF54 Challenge Strains (PfSPZ) in a Head-to-head Comparative Study - (ECG-CHMI)

    NCT04203186 · start 2020-03

    Registered record
    Registry ID
    NCT04203186
    Conditions
    Plasmodium Falciparum
    Interventions
    atovaquone-proguanil
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2020-03
    Completion
    2021-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasmodium Falciparum
    Interventionatovaquone-proguanil
    PhaseNot applicable
    Registry statusWithdrawn

  • Malarone Pharmacokinetics Under Simulated Physiologic Stressors of Deployment

    NCT03991208 · start 2019-05-24

    Registered record
    Registry ID
    NCT03991208
    Conditions
    Exercise; Pharmacokinetics
    Interventions
    Malarone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2019-05-24
    Completion
    2021-05-23
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExercise; Pharmacokinetics
    InterventionMalarone
    PhasePhase 4
    Registry statusWithdrawn

  • Safety and Efficacy of NF135 CPS Immunization

    NCT03813108 · start 2019-04-01

    Registered record
    Registry ID
    NCT03813108
    Conditions
    Malaria,Falciparum; Controlled Human Malaria Infection; Immunization; Infection
    Interventions
    CPS-immunization; malaria challenge infection, P. falciparum NF135.C10; malaria challenge infection, P. falciparum NF54; CPS-immunization (A/L); Atovaquone / Proguanil Oral Tablet [Malarone]
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2019-04-01
    Completion
    2021-02-01
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria,Falciparum; Controlled Human Malaria Infection; Immunization; Infection
    InterventionCPS-immunization; malaria challenge infection, P. falciparum NF135.C10; malaria challenge infection, P. falciparum NF54; CPS-immunization (A/L) +1 more
    PhaseNot applicable
    Registry statusTerminated

  • Drug Combinations of Atovaquone-Proguanil (AP) With ACT

    NCT03726593 · start 2018-10-04

    Registered record
    Registry ID
    NCT03726593
    Conditions
    Plasmodium Falciparum Malaria (Drug Resistant)
    Interventions
    Artesunate and Pyronaridine; Atovaquone Proguanil and Artesunate Pyronaridine; Atovaquone Proguanil and Artesunate Mefloquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-10-04
    Completion
    2022-12-30
    Enrolment
    252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasmodium Falciparum Malaria (Drug Resistant)
    InterventionArtesunate and Pyronaridine; Atovaquone Proguanil and Artesunate Pyronaridine; Atovaquone Proguanil and Artesunate Mefloquine
    PhasePhase 4
    Registry statusUnknown

  • Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis

    NCT03278808 · start 2018-09-17

    Registered record
    Registry ID
    NCT03278808
    Conditions
    Malaria
    Interventions
    Chloroquine-Azithromycin (CQ/AZ); Chloroquine (CQ); atovaquone-proguanil (Malarone®)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2018-09-17
    Completion
    2020-01-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionChloroquine-Azithromycin (CQ/AZ); Chloroquine (CQ); atovaquone-proguanil (Malarone®)
    PhasePhase 2
    Registry statusWithdrawn